Barclays Increases Humana (NYSE:HUM) Price Target to $255.00

Humana (NYSE:HUM) had its price target lifted by investment analysts at Barclays from $253.00 to $255.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the insurance provider’s stock. Barclays‘s price objective points to a potential downside of 13.03% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and raised their price objective for the company from $247.00 to $308.00 in a report on Wednesday, November 6th. Cantor Fitzgerald restated a “neutral” rating and issued a $395.00 price objective on shares of Humana in a report on Tuesday, October 1st. Piper Sandler lifted their target price on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 15th. Leerink Partners lowered shares of Humana from an “outperform” rating to a “market perform” rating and cut their price target for the company from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Finally, KeyCorp began coverage on Humana in a report on Friday, October 11th. They issued a “sector weight” rating on the stock. Twenty equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus price target of $302.80.

Humana Stock Up 2.9 %

Shares of NYSE HUM opened at $293.22 on Wednesday. The business has a 50-day moving average of $273.81 and a 200-day moving average of $305.88. The firm has a market capitalization of $35.31 billion, a price-to-earnings ratio of 25.97, a PEG ratio of 2.15 and a beta of 0.55. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana has a 12 month low of $213.31 and a 12 month high of $411.80.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Sell-side analysts expect that Humana will post 16.11 earnings per share for the current fiscal year.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This represents a 31.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.32% of the company’s stock.

Institutional Investors Weigh In On Humana

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Financial Designs Inc. ADV boosted its position in shares of Humana by 244.0% in the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 61 shares in the last quarter. Atwood & Palmer Inc. purchased a new position in Humana during the third quarter valued at $29,000. Ashton Thomas Securities LLC purchased a new position in Humana during the third quarter valued at $31,000. Your Advocates Ltd. LLP boosted its holdings in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after acquiring an additional 45 shares in the last quarter. Finally, LRI Investments LLC increased its holdings in shares of Humana by 1,021.4% during the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock valued at $50,000 after acquiring an additional 143 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.